The long-term antibody persistence of GSK Biologicals' MenACWY-TT vaccine (GSK134612) versus Meningitec or Mencevax ACWY in healthy adolescents and adults and booster response to MenACWY-TT administered 10 years post-primary vaccination

Trial Profile

The long-term antibody persistence of GSK Biologicals' MenACWY-TT vaccine (GSK134612) versus Meningitec or Mencevax ACWY in healthy adolescents and adults and booster response to MenACWY-TT administered 10 years post-primary vaccination

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; Pfizer
  • Most Recent Events

    • 02 Mar 2016 Planned number of patients changed to 488 as reported by European Clinical Trials Database record.
    • 20 Nov 2015 Planned End Date changed from 1 May 2018 to 1 Jun 2018 as per ClinicalTrials.gov record.
    • 20 Nov 2015 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top